

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

## **RELEVANT EVENT**

Grifols has obtained a new long-term loan with the European Investment Bank (EIB) totaling Euros 85 million. Grifols will use this loan to support its R+D+i initiatives which are primarily focused on discovering new indications for plasma-derived protein therapies.

The financial conditions include a fixed interest rate for a tenor of 10 years and a two-year grace period.

Grifols was among the first European companies to obtain funding through the European Fund for Strategic Investment when it signed its first EIB loan for Euros 100 million in 2015.

In Barcelona, on 5 December 2017

---

Nuria Martín Barnés  
Secretary to the Board of Directors